Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37278194

about

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy.Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients Local recurrence of hepatocellular carcinoma after radiofrequency ablation.Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis.How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study.Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis.Antiviral therapy in patients with chronic hepatitis B and hepatocellular carcinoma: post-thermal ablation. Better late than never?Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma.How does hepatitis B virus infection react to hepatocellular carcinoma treatment?Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation.Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions.Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis

P2860

Q24234212-CF7481F0-B8EC-4C1C-B88C-32200ABCD5D3 Q24236020-63474232-79E6-43E6-A2B5-16D553DFB6AE Q26742104-FCA5B919-E179-4B97-8827-F0F2F3A30185 Q26799056-43462BD8-E8BA-4590-8371-33436052865A Q26998178-A82121DA-78CE-4719-AC76-7E919D41A9A8 Q28392783-09AAD16F-D9B6-4C13-83BA-7ACA8C30561B Q28394414-BE5D3098-6E47-491F-B39C-7760244B917C Q30234870-8F85B9A1-666A-4327-B396-9C693123D013 Q33904007-E2979EA5-E412-43CD-83A5-E5C6DCFBA7CA Q35562753-6C442447-AF0C-43BB-AAB3-C6C5CD6C15FF Q36335540-59035E11-0CEE-4B48-8701-06E41B2D9CA8 Q36406952-519D51B7-8744-4F53-BECD-9F502885C912 Q36874995-5950796C-50F4-4F6F-A5D9-9EC179F59289 Q37229870-4D6B2AC9-ABD2-4491-9DDA-B09CA3274DCF Q37803179-ACC1A138-8668-4A84-8BCD-32B0F0ECD323 Q38224439-DB7F4BAC-7C50-4408-9D2E-B33FF9E4E02F Q38256154-4D8D00A8-F80C-4131-A934-72AB084EB6DC Q38545840-7D216044-8A4E-4F19-8F45-61EE3F555A6A Q38578909-04957DDA-4390-4E37-98E3-646FFB5DC4F8 Q38718402-452D7AD9-55BA-43FD-9FF6-8C26D12994DB Q39674275-4048C3F4-6857-49A3-AE8E-81B61D769305 Q42181000-7B5998A0-65D8-49B6-B14F-151BA0FBA20C Q42439028-5640551C-4E12-4A60-8176-BAEA2C680437 Q42591154-57835338-612D-45CA-BC75-7DCC4083459E Q44256705-4DB6BAC1-7F41-4B31-9883-01B25EAB0897 Q45360920-19C6C9C8-7796-4BA3-AD67-0CDF7B2645AA Q46339113-62744E07-4629-4B64-BCB2-B5D96290C691 Q51790205-7D007C6A-1ACB-4AC8-8E09-6D85BC9B9B29 Q58776031-A23DA104-D82B-463D-9100-3196DB19EB85

P2860

Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37278194

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 September 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@en

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@nl

type

label

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@en

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@nl

prefLabel

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@en

Safety and efficacy of lamivud ...... ated hepatocellular carcinoma.

@nl

P1433

Q37278194-7C1A2E3A-CFB3-4B76-8913-ECE7486A5C1F

P1476

Q37278194-2D704948-3C6A-45EF-B3C3-4025B6BDC8A9

P2093

Q37278194-0594270D-D669-45AC-9ABC-2FCDB7BAD501

Q37278194-46116D83-D976-4D24-B00B-CA2BE00D535B

Q37278194-46A4603F-22B6-4E70-AE60-3D38AAB4F30A

Q37278194-8DF99149-5A00-4BD9-AB46-6AB1A2179ACC

Q37278194-987E1F4E-4A07-475D-BA65-6950DB732B04

Q37278194-B5C0923E-2FAE-408F-89BA-51D4F97F07AC

Q37278194-B75FB884-A2F4-4668-9303-97D7F957F3C7

Q37278194-B8825D22-2885-400D-8622-E172013FD769

Q37278194-D591B152-9E4D-4E47-9690-CA99B679E1A3

Q37278194-EAF358A5-857E-4B7D-8654-C80E3D944691

P2860

Q37278194-20AA9A8D-8AF6-4C8B-9548-76F650ACC3B3

Q37278194-277C7CAA-037B-446A-BBC6-5AAED07346C3

Q37278194-280E6381-8265-4857-886D-8DED99DBBB73

Q37278194-28300C17-8079-4596-B145-BCA12D633E3F

Q37278194-55DBA5B6-EC7C-4F24-BD72-79AEEF2EED82

Q37278194-5DFC9199-2EF2-432B-8E2E-FEE8C9D514C4

Q37278194-867BEA9F-655B-4743-8771-F6BE96F77751

Q37278194-8886FB6A-CEA4-4BDC-8FD5-06BB93085D22

Q37278194-92E9CCBC-1C7B-43C8-A0F9-E4567C6D321F

Q37278194-9CB30B4A-BB5C-4EB2-9ED8-44A4A9FF701D

P2888

Q37278194-24FD7960-18BE-4ED0-89B7-60E811F534C7

P304

Q37278194-F2A0A4A6-F2E1-4B5F-9537-E92BB1D51D0C

P31

Q37278194-BAD79E51-2C6F-417D-9D6C-A078D2E46A0B

P356

Q37278194-0B45A06C-A87B-4845-8C38-B3B22F2B0AE4

P433

Q37278194-40EA90AC-2274-4603-A0B4-411302B13F47

P478

Q37278194-CF649F39-9640-4CB3-A200-AA83B00109A3

P50

Q37278194-C130A1A5-000D-4942-829D-5FA73B635D15

P577

Q37278194-2BC9197A-727E-4A0A-AC3C-7988CDBA8022

P5875

Q37278194-B590C7FC-C477-4D34-9912-E3A2D442C7D1

P698

Q37278194-9046FB02-4CF4-4BEE-8354-2EF722127B53

P932

Q37278194-185B4AB8-1578-49C6-97E9-5029C3BE3905

P356

S12072-007-9020-7

P1433

Hepatology international

P1476

Safety and efficacy of lamivud ...... lated hepatocellular carcinoma

@en

P2093

Eriko Goto

http://www.w3.org/2001/XMLSchema#string

Haruhiko Yoshida

http://www.w3.org/2001/XMLSchema#string

Hideo Yoshida

http://www.w3.org/2001/XMLSchema#string

Masao Omata

http://www.w3.org/2001/XMLSchema#string

Ryota Masuzaki

http://www.w3.org/2001/XMLSchema#string

Shuichiro Shiina

http://www.w3.org/2001/XMLSchema#string

Tadashi Goto

http://www.w3.org/2001/XMLSchema#string

Takahisa Sato

http://www.w3.org/2001/XMLSchema#string

Takamasa Ohki

http://www.w3.org/2001/XMLSchema#string

Takao Kawabe

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.

P2888

s12072-007-9020-7

P304

89-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-007-9020-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Ryosuke Tateishi

P577

2007-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26730849

http://www.w3.org/2001/XMLSchema#string

P698

19669283

http://www.w3.org/2001/XMLSchema#string

P932

2716870

http://www.w3.org/2001/XMLSchema#string